These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 27075627)
81. Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis. Yang Z; Xu H; Yang Y; Duan C; Zhang P; Wang Y; Fu K; Shen Y; Xu MX Breast Cancer Res Treat; 2023 Jan; 197(2):255-267. PubMed ID: 36369502 [TBL] [Abstract][Full Text] [Related]
82. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Datta A; Loo SY; Huang B; Wong L; Tan SS; Tan TZ; Lee SC; Thiery JP; Lim YC; Yong WP; Lam Y; Kumar AP; Yap CT Oncotarget; 2014 Aug; 5(15):5920-33. PubMed ID: 25153718 [TBL] [Abstract][Full Text] [Related]
83. Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer. Singh P; Sahoo SK Int J Pharm; 2022 Mar; 616():121526. PubMed ID: 35104598 [TBL] [Abstract][Full Text] [Related]
84. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Turner N; Lambros MB; Horlings HM; Pearson A; Sharpe R; Natrajan R; Geyer FC; van Kouwenhove M; Kreike B; Mackay A; Ashworth A; van de Vijver MJ; Reis-Filho JS Oncogene; 2010 Apr; 29(14):2013-23. PubMed ID: 20101236 [TBL] [Abstract][Full Text] [Related]
85. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Chen YY; Ge JY; Zhu SY; Shao ZM; Yu KD Nat Commun; 2022 Feb; 13(1):791. PubMed ID: 35145111 [TBL] [Abstract][Full Text] [Related]
86. Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. Chernikova SB; Nguyen RB; Truong JT; Mello SS; Stafford JH; Hay MP; Olson A; Solow-Cordero DE; Wood DJ; Henry S; von Eyben R; Deng L; Gephart MH; Aroumougame A; Wiese C; Game JC; Győrffy B; Brown JM J Clin Invest; 2018 Dec; 128(12):5307-5321. PubMed ID: 30371505 [TBL] [Abstract][Full Text] [Related]
87. Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer. Stenckova M; Nenutil R; Vojtesek B; Coates PJ Pathol Oncol Res; 2022; 28():1610592. PubMed ID: 36017196 [TBL] [Abstract][Full Text] [Related]
88. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Walker SR; Liu S; Xiang M; Nicolais M; Hatzi K; Giannopoulou E; Elemento O; Cerchietti L; Melnick A; Frank DA Oncogene; 2015 Feb; 34(9):1073-82. PubMed ID: 24662818 [TBL] [Abstract][Full Text] [Related]
89. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Meier C; Hoeller S; Bourgau C; Hirschmann P; Schwaller J; Went P; Pileri SA; Reiter A; Dirnhofer S; Tzankov A Mod Pathol; 2009 Mar; 22(3):476-87. PubMed ID: 19136931 [TBL] [Abstract][Full Text] [Related]
90. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Iwakawa R; Takenaka M; Kohno T; Shimada Y; Totoki Y; Shibata T; Tsuta K; Nishikawa R; Noguchi M; Sato-Otsubo A; Ogawa S; Yokota J Genes Chromosomes Cancer; 2013 Sep; 52(9):802-16. PubMed ID: 23716474 [TBL] [Abstract][Full Text] [Related]
91. Cooperative epigenetic modulation by cancer amplicon genes. Rui L; Emre NC; Kruhlak MJ; Chung HJ; Steidl C; Slack G; Wright GW; Lenz G; Ngo VN; Shaffer AL; Xu W; Zhao H; Yang Y; Lamy L; Davis RE; Xiao W; Powell J; Maloney D; Thomas CJ; Möller P; Rosenwald A; Ott G; Muller-Hermelink HK; Savage K; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Weisenburger DD; Chan WC; Gascoyne RD; Levens D; Staudt LM Cancer Cell; 2010 Dec; 18(6):590-605. PubMed ID: 21156283 [TBL] [Abstract][Full Text] [Related]
92. An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer. Jacobo Jacobo M; Donnella HJ; Sobti S; Kaushik S; Goga A; Bandyopadhyay S Sci Rep; 2024 Feb; 14(1):3694. PubMed ID: 38355954 [TBL] [Abstract][Full Text] [Related]
93. Identification of novel inhibitors from Urtica spp against TNBC targeting JAK2 receptor for breast cancer therapy. Upreti S; Muduli K; Pradhan J; Elangovan S; Samant M Med Oncol; 2023 Oct; 40(11):326. PubMed ID: 37806999 [TBL] [Abstract][Full Text] [Related]
94. De novo design of dual-target JAK2, SMO inhibitors based on deep reinforcement learning, molecular docking and molecular dynamics simulations. He L; Liu J; Zhao HL; Zhang LC; Yu RL; Kang CM Biochem Biophys Res Commun; 2023 Jan; 638():23-27. PubMed ID: 36436338 [TBL] [Abstract][Full Text] [Related]
96. Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. Kuhlmann L; Govindarajan M; Mejia-Guerrero S; Ignatchenko V; Liu LY; Grünwald BT; Cruickshank J; Berman H; Khokha R; Kislinger T J Proteome Res; 2022 Sep; 21(9):2224-2236. PubMed ID: 35981243 [TBL] [Abstract][Full Text] [Related]
97. Detection of JAK2 gene mutation in Pakistani women with triple-negative breast cancer. Naeem MA; Shah TH; Zafar N; Khan M; Bhutto AA; Rabbani S Breast J; 2020 Apr; 26(4):829-830. PubMed ID: 31513718 [No Abstract] [Full Text] [Related]
98. Gene copy number variations in breast cancer of Sub-Saharan African women. Ly M; Valent A; Diallo G; Penault-Lorca F; Dumke K; Marty V; Viehl P; Lazar V; Job B; Richon C; Scott V; Diallo DA; Bernaudin JF; Andre F Breast; 2013 Jun; 22(3):295-300. PubMed ID: 22999459 [TBL] [Abstract][Full Text] [Related]
99. Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles. Tošić I; Heppler LN; Egusquiaguirre SP; Boehnke N; Correa S; Costa DF; Moore EAG; Pal S; Richardson DS; Ivanov AR; Haas-Kogan DA; Nomura DK; Hammond PT; Frank DA Mol Cancer Ther; 2021 Apr; 20(4):726-738. PubMed ID: 33536189 [TBL] [Abstract][Full Text] [Related]
100. Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. Patel N; Weekes D; Drosopoulos K; Gazinska P; Noel E; Rashid M; Mirza H; Quist J; Brasó-Maristany F; Mathew S; Ferro R; Pereira AM; Prince C; Noor F; Francesch-Domenech E; Marlow R; de Rinaldis E; Grigoriadis A; Linardopoulos S; Marra P; Tutt ANJ Nat Commun; 2018 Mar; 9(1):1044. PubMed ID: 29535384 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]